Home › Funds › Novo Holdings A/S › FDMT
Novo Holdings A/S position in FDMT
4D MOLECULAR THERAPEUTICS IN · Health Care
Novo Holdings A/S reported holding 3,000,000 shares of FDMT (4D MOLECULAR THERAPEUTICS IN) in its Q3 2026 13F filing — a position valued at US$42.9M, representing 2.88% of its reported portfolio and ranking #10 among its reported holdings. Novo Holdings A/S has disclosed FDMT holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR
How Novo Holdings A/S's FDMT position evolved
Novo Holdings A/S first disclosed a stake in FDMT in Q3 2023 at 1,200,000 shares (US$15.3M). The position peaked in Q1 2024 at 1,400,000 shares, worth US$44.6M. Across 13 filings, Novo Holdings A/S increased the stake 5 time(s), trimmed it 3 time(s) and left it unchanged 4 time(s). The most recent filing (Q3 2026) shows 3,000,000 shares valued at US$42.9M — a reduction of -249,178 shares quarter over quarter.. Notable position changes include a 25% increase in Q4 2023 (shares rose 57% over the following quarter), a 30% increase in Q1 2025 (shares rose 15% over the following quarter), a 83% increase in Q4 2025 (shares rose 24% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 1.20M | $15.28M | New |
| Q4 2023 | 1.50M | $30.39M | Add |
| Q1 2024 | 1.40M | $44.60M | Reduce |
| Q2 2024 | 1.40M | $29.39M | Hold |
| Q3 2024 | 1.50M | $16.21M | Add |
| Q4 2024 | 1.50M | $8.36M | Hold |
| Q1 2025 | 1.95M | $6.30M | Add |
| Q2 2025 | 2.00M | $7.42M | Add |
| Q3 2025 | 2.00M | $17.38M | Hold |
| Q4 2025 | 3.65M | $27.38M | Add |
| Q1 2026 | 3.65M | $33.99M | Hold |
| Q2 2026 | 3.25M | $43.21M | Reduce |
| Q3 2026 | 3.00M | $42.93M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About FDMT and 13F data
FDMT (4D MOLECULAR THERAPEUTICS IN) is a Health Care company. 30 other funds we track also report a position in FDMT — the largest reported positions include RA CAPITAL MANAGEMENT, L.P. (US$72.3M), BVF INC/IL (US$41.2M), Trails Edge Capital Partners, LP (US$31.9M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding FDMT
- RA CAPITAL MANAGEMENT, L.P. 5.05M sh · $72.26M · Q3 2026
- BVF INC/IL 2.88M sh · $41.20M · Q3 2026
- Trails Edge Capital Partners, LP 2.23M sh · $31.88M · Q3 2026
- ARMISTICE CAPITAL, LLC 1.95M sh · $27.90M · Q3 2026
- Evergreen Quality Fund GP, Ltd. 951.47K sh · $13.62M · Q3 2026
- Parkman Healthcare Partners LLC 772.18K sh · $11.05M · Q3 2026
- Catalio Capital Management, LP 684.75K sh · $9.80M · Q3 2026
- ACUTA CAPITAL PARTNERS, LLC 535.11K sh · $7.66M · Q3 2026
- DIADEMA PARTNERS LP 421.11K sh · $6.03M · Q3 2026
More on Novo Holdings A/S
FAQ
How long has Novo Holdings A/S held FDMT?
Novo Holdings A/S has disclosed FDMT holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
What is Novo Holdings A/S's current position in FDMT?
As of Q3 2026, Novo Holdings A/S holds 3.00M shares of FDMT (4D MOLECULAR THERAPEUTICS IN), valued at $42.93M, representing 2.88% of its reported portfolio and ranking #10.
Has Novo Holdings A/S been buying or selling FDMT?
In the latest 13F filing (Q3 2026), Novo Holdings A/S reduced its position in FDMT. The position peaked in Q1 2024 at 1.40M shares.
Which other funds hold FDMT?
Other major institutional holders of FDMT include RA CAPITAL MANAGEMENT, L.P., BVF INC/IL, Trails Edge Capital Partners, LP, among 30 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.